Education
About Us
Working with TipRanks
Follow Us
Adagene (ADAG)
NASDAQ:ADAG
Pembrolizumab (Keytruda®), Adg126, Standard Of Care (Trifluridine/Tipiracil-Bevacizumab), Standard Of Care (Fruquintinib)
Advanced/Metastatic Solid Tumors
Phase I/II
Recruiting
ADG126 in Combination With Pembrolizumab in Patients With Advanced/Metastatic Solid Tumors
May 16, 2022
―
Atezolizumab, Nkt2152, Adg126, Tocilizumab, Tpst-1120, Tiragolumab, Bevacizumab 10 Mg/Kg, Bevacizumab 15 Mg/Kg, Tobemstomig 2100 Mg, Tobemstomig 600 Mg, Tobemstomig 1200 Mg, Io-108 1800 Mg, Io-108 1200 Mg
Advanced Liver Cancers
Phase I/II
Recruiting
A Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combinations in Patients With Advanced Liver Cancers (Morpheus-Liver)
Aug 21, 2020
―
FAQ
What are the FDA phases for drug approval?
The FDA approval process for new drugs is divided into several phases:
a. Preclinical testing
b. Phase 1 – Safety and dosage
c. Phase 2 – Effectiveness and side effects
d. Phase 3 – Confirmation of effectiveness, monitoring of adverse reactions, and comparison with existing treatments
e. Phase 4 – Post-marketing studies to track long-term safety and effectiveness
a. Preclinical testing
b. Phase 1 – Safety and dosage
c. Phase 2 – Effectiveness and side effects
d. Phase 3 – Confirmation of effectiveness, monitoring of adverse reactions, and comparison with existing treatments
e. Phase 4 – Post-marketing studies to track long-term safety and effectiveness
What is a clinical trial?
A clinical trial is a carefully designed study in which researchers test a drug, treatment, or medical device in people to evaluate its safety, effectiveness, and potential side effects. These trials are essential for determining whether a new treatment should be approved for widespread use.
What drugs does Adagene (ADAG) have in its pipeline
ADAG is currently developing the following drugs: Pembrolizumab (Keytruda®), Adg126, Standard Of Care (Trifluridine/Tipiracil-Bevacizumab), Standard Of Care (Fruquintinib), Atezolizumab, Nkt2152, Adg126, Tocilizumab, Tpst-1120, Tiragolumab, Bevacizumab 10 Mg/Kg, Bevacizumab 15 Mg/Kg, Tobemstomig 2100 Mg, Tobemstomig 600 Mg, Tobemstomig 1200 Mg, Io-108 1800 Mg, Io-108 1200 Mg. These drug candidates are in various stages of clinical development as the company works toward FDA approval.